Alder Biopharmaceuticals, Inc.
(NASDAQ : ALDR)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. 2.25%44.950.9%$1187.06m
JNJJohnson & Johnson 0.98%173.950.7%$1052.86m
AZNAstraZeneca Plc 0.39%57.611.0%$1030.33m
ABBVAbbVie, Inc. -0.23%115.181.9%$667.83m
MRKMerck & Co., Inc. 0.62%76.650.7%$652.98m
LLYEli Lilly & Co. 4.03%256.531.1%$615.06m
BMYBristol-Myers Squibb Co. 1.10%68.771.0%$586.98m
NRXPNRX Pharmaceuticals, Inc. -2.28%15.830.0%$185.90m
GSKGlaxoSmithKline Plc 0.63%40.490.2%$161.84m
NVSNovartis AG 0.09%92.350.2%$153.59m
RGENRepligen Corp. 0.08%248.076.8%$99.33m
VTRSViatris, Inc. -0.95%14.100.0%$86.76m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.35%118.420.0%$85.86m
NVONovo Nordisk A/S 0.04%93.040.1%$84.14m
RPRXRoyalty Pharma Plc -1.25%36.750.2%$81.22m

Company Profile

Alder's mission is to help alleviate human suffering by generating better and safer antibody therapeutics through novel technologies. Alder plays two roles: As a biopharmaceutical company, Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases. As a licensing partner, Alder is revolutionizing the way the pharmaceutical industry discovers, develops and produces antibody therapeutics. Through various licensing agreements, Alder has used its proprietary technology to help major biopharmaceutical partners advance novel therapeutics to the clinic in less time and at lower cost. Alder's licensing strategy also includes identifying strategic partners to assist in the development and marketing of its preclinical and clinical pipeline programs.